RecruitingNCT05126290

CTNNA1 Familial Expansion Study

CTNNA1 Familial Expansion (CAFÉ) Study


Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

100 participants

Start Date

Mar 16, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (the CTNNA1 Familial Expansion Study) is collecting clinical data and biological samples from people who carry a loss-of-function variant in the CTNNA1 gene, or who are a close relative of someone who does. CTNNA1 mutations are linked to a hereditary form of diffuse gastric cancer. The goal is to better understand how this genetic variant is associated with cancer risk and other health outcomes over time. **You may be eligible if...** - You are 18 or older - You carry a CTNNA1 loss-of-function variant (a genetic change that disrupts the gene's function), OR you are a first-degree relative (parent, sibling, or child) of someone who does - You can read and understand English and provide informed consent **You may NOT be eligible if...** - You are under 18 - You do not carry the variant and are not a direct family member of a carrier - You cannot speak or read English - You have major psychiatric illness or cognitive impairment that would prevent you from participating Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCollection of personal and family history from CAFÉ Study participants

Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system


Locations(1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05126290


Related Trials